Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 55, Issue 12, Pages 1919-1922Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.114.146019
Keywords
theranostic nanoparticle; cancer; active targeting; theranostics; nanomedicine
Funding
- University of Wisconsin-Madison
- National Institutes of Health [NIBIB/NCI 1R01CA169365, P30CA014520]
- Department of Defense [W81XWH-11-1-0644]
- American Cancer Society [125246-RSG-13-099-01-CCE]
- NATIONAL CANCER INSTITUTE [R01CA169365, P30CA014520] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Theranostic nanoparticles hold the potential to revolutionize disease management. Over the last decade, there has been growing interest in the engineering of various kinds of theranostic nanoparticles for simultaneous cancer imaging and therapy in small animals. Efficient targeting of theranostic nanoparticles to the tumor site is critical for both diagnosis and therapy. However, difficulties still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor-targeting capabilities. Here, we discuss the current and prospective status of theranostic nanoparticles that actively target tumors, as well as the challenges that still exist.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available